{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T18:06:27Z","timestamp":1783015587052,"version":"3.54.6"},"reference-count":42,"publisher":"MDPI AG","issue":"20","license":[{"start":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T00:00:00Z","timestamp":1760054400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003725","name":"Ministry of Science","doi-asserted-by":"publisher","award":["NRF-2017R1A2B2003428"],"award-info":[{"award-number":["NRF-2017R1A2B2003428"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003645","name":"National Cancer Center of Korea","doi-asserted-by":"crossref","award":["NCC 2410891-1"],"award-info":[{"award-number":["NCC 2410891-1"]}],"id":[{"id":"10.13039\/501100003645","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003645","name":"National Cancer Center of Korea","doi-asserted-by":"crossref","award":["NCC 2410892-1"],"award-info":[{"award-number":["NCC 2410892-1"]}],"id":[{"id":"10.13039\/501100003645","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003645","name":"National Cancer Center of Korea","doi-asserted-by":"crossref","award":["NCC 24H1210-1"],"award-info":[{"award-number":["NCC 24H1210-1"]}],"id":[{"id":"10.13039\/501100003645","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Immunotherapy and RAF-targeted therapy have become standard treatments for melanoma, significantly improving outcomes compared to earlier therapies. When resistance to initial treatment develops, the older chemotherapy drug Dacarbazine is used. However, resistance to both therapies has emerged, promoting ongoing research to further enhance survival rates. Among various theories, autophagy is believed to play a critical role in acquired drug resistance, as increased autophagy has been observed in resistance to multiple anticancer agents. In this study, Dabrafenib was administered to melanoma cells with an RAF mutation, while Dacarbazine was given to cells with an Raf wild type. Both cell lines showed increased autophagy and FAO following treatment with the anticancer drugs. When FAO was blocked during drug treatment, melanoma cells became more susceptible to cell death. In xenograft models, B16F10 melanoma (Raf wild type) demonstrated regrowth due to acquired resistance after two weeks of Dacarbazine treatment. Conversely, a combination of Dacarbazine and the FAO inhibitors KN510 and KN713 (a combination of KN510 and KN713:KN510713) caused near-complete remission without regrowth. A375 melanoma (BRAFV600E) developed resistance after four weeks of Dabrafenib treatment, yet the combination of Dabrafenib and KN510713 resulted in near-complete remission with no signs of regrowth. Based on these findings, combining FAO inhibitors with first-line therapies may be a promising approach for managing melanoma, regardless of RAF mutation status.<\/jats:p>","DOI":"10.3390\/ijms26209873","type":"journal-article","created":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:50:16Z","timestamp":1760107816000},"page":"9873","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Inhibiting Fatty Acid Oxidation Suppresses Acquired Resistance to Standard Chemotherapy in Melanoma"],"prefix":"10.3390","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8292-3903","authenticated-orcid":false,"given":"Wonyoung","family":"Choi","sequence":"first","affiliation":[{"name":"Department of Cancer Biomedical Science, National Cancer Center Graduate School of Cancer Science and Policy, Goyang 10408, Republic of Korea"},{"name":"Division of Cancer Biology, Research Institute of National Cancer Center, Goyang 10408, Republic of Korea"},{"name":"Therapeutic Resistance Research Branch, Research Institute and Hospital, National Cancer Center, Goyang 10408, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Woojin","family":"Ham","sequence":"additional","affiliation":[{"name":"Division of Cancer Biology, Research Institute of National Cancer Center, Goyang 10408, Republic of Korea"},{"name":"New Cancer Cure-Bio Co., Goyang 10408, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeong Hwan","family":"Park","sequence":"additional","affiliation":[{"name":"Division of Cancer Biology, Research Institute of National Cancer Center, Goyang 10408, Republic of Korea"},{"name":"New Cancer Cure-Bio Co., Goyang 10408, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1503-1075","authenticated-orcid":false,"given":"Sung Hoon","family":"Sim","sequence":"additional","affiliation":[{"name":"Division of Rare and Refractory Cancer, Research Institute, National Cancer Center, Goyang 10408, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1964-7501","authenticated-orcid":false,"given":"Jung Won","family":"Chun","sequence":"additional","affiliation":[{"name":"Department of Cancer Biomedical Science, National Cancer Center Graduate School of Cancer Science and Policy, Goyang 10408, Republic of Korea"},{"name":"Division of Clinical Research, Research Institute, National Cancer Center, Goyang 10408, Republic of Korea"},{"name":"Center for Liver and Pancreatobiliary Cancer, National Cancer Center, Goyang 10408, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingyu","family":"Kang","sequence":"additional","affiliation":[{"name":"Division of Cancer Biology, Research Institute of National Cancer Center, Goyang 10408, Republic of Korea"},{"name":"New Cancer Cure-Bio Co., Goyang 10408, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaeyoung","family":"Kim","sequence":"additional","affiliation":[{"name":"Division of Cancer Biology, Research Institute of National Cancer Center, Goyang 10408, Republic of Korea"},{"name":"New Cancer Cure-Bio Co., Goyang 10408, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Woosol","family":"Hong","sequence":"additional","affiliation":[{"name":"Division of Cancer Biology, Research Institute of National Cancer Center, Goyang 10408, Republic of Korea"},{"name":"New Cancer Cure-Bio Co., Goyang 10408, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eun-Byeol","family":"Koh","sequence":"additional","affiliation":[{"name":"Division of Cancer Biology, Research Institute of National Cancer Center, Goyang 10408, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joon Hee","family":"Kang","sequence":"additional","affiliation":[{"name":"Department of Cancer Biomedical Science, National Cancer Center Graduate School of Cancer Science and Policy, Goyang 10408, Republic of Korea"},{"name":"New Cancer Cure-Bio Co., Goyang 10408, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3786-4403","authenticated-orcid":false,"given":"Sang Myung","family":"Woo","sequence":"additional","affiliation":[{"name":"Department of Cancer Biomedical Science, National Cancer Center Graduate School of Cancer Science and Policy, Goyang 10408, Republic of Korea"},{"name":"Division of Rare and Refractory Cancer, Research Institute, National Cancer Center, Goyang 10408, Republic of Korea"},{"name":"Center for Liver and Pancreatobiliary Cancer, National Cancer Center, Goyang 10408, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4021-2206","authenticated-orcid":false,"given":"Soo-Youl","family":"Kim","sequence":"additional","affiliation":[{"name":"Division of Cancer Biology, Research Institute of National Cancer Center, Goyang 10408, Republic of Korea"},{"name":"New Cancer Cure-Bio Co., Goyang 10408, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,10,10]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa2407417","article-title":"Final, 10-Year Outcomes with Nivolumab plus Ipilimumab in Advanced Melanoma","volume":"392","author":"Wolchok","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus Ipilimumab in Advanced Melanoma","volume":"372","author":"Robert","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1056\/NEJMoa1904059","article-title":"Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma","volume":"381","author":"Robert","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1056\/NEJMoa1104621","article-title":"Ipilimumab plus dacarbazine for previously untreated metastatic melanoma","volume":"364","author":"Robert","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1001\/jamaoncol.2018.4514","article-title":"Survival Outcomes in Patients with Previously Untreated BRAF Wild-Type Advanced Melanoma Treated with Nivolumab Therapy: Three-Year Follow-up of a Randomized Phase 3 Trial","volume":"5","author":"Ascierto","year":"2019","journal-title":"JAMA Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s12935-024-03220-9","article-title":"Melanoma biology and treatment: A review of novel regulated cell death-based approaches","volume":"24","author":"Hsieh","year":"2024","journal-title":"Cancer Cell Int."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.ejca.2022.04.018","article-title":"European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment-Update 2022","volume":"170","author":"Garbe","year":"2022","journal-title":"Eur. J. Cancer"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2694","DOI":"10.1093\/annonc\/mdt291","article-title":"Efficacy and safety of ipilimumab in metastatic melanoma patients surviving more than 2 years following treatment in a phase III trial (MDX010-20)","volume":"24","author":"McDermott","year":"2013","journal-title":"Ann. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1200\/JCO.22.01763","article-title":"Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients with Advanced BRAF-Mutant Melanoma: The DREAMseq Trial-ECOG-ACRIN EA6134","volume":"41","author":"Atkins","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1056\/NEJMoa1112302","article-title":"Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib","volume":"366","author":"Sosman","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1056\/NEJMoa1412690","article-title":"Improved overall survival in melanoma with combined dabrafenib and trametinib","volume":"372","author":"Robert","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"e371","DOI":"10.1016\/S1470-2045(14)70072-5","article-title":"Systemic treatment for BRAF-mutant melanoma: Where do we go next?","volume":"15","author":"Menzies","year":"2014","journal-title":"Lancet Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2581","DOI":"10.1093\/annonc\/mdx339","article-title":"Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: Final overall survival results of the randomized BRIM-3 study","volume":"28","author":"Chapman","year":"2017","journal-title":"Ann. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1038\/s41416-021-01486-8","article-title":"Impact of prior treatment with immune checkpoint inhibitors on dacarbazine efficacy in metastatic melanoma","volume":"125","author":"Bouchereau","year":"2021","journal-title":"Br. J. Cancer"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.phrs.2007.08.003","article-title":"Triazene compounds: Mechanism of action and related DNA repair systems","volume":"56","author":"Marchesi","year":"2007","journal-title":"Pharmacol. Res."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1200\/JCO.2000.18.1.158","article-title":"Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma","volume":"18","author":"Middleton","year":"2000","journal-title":"J. Clin. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1007\/s11912-023-01385-6","article-title":"Chemotherapy in Cutaneous Melanoma: Is There Still a Role?","volume":"25","author":"Pham","year":"2023","journal-title":"Curr. Oncol. Rep."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"730","DOI":"10.4143\/crt.2019.598","article-title":"Clinical Outcomes of Immune Checkpoint Blocker Therapy for Malignant Melanoma in Korean Patients: Potential Clinical Implications for a Combination Strategy Involving Radiotherapy","volume":"52","author":"Lee","year":"2020","journal-title":"Cancer Res. Treat."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1038\/s41580-023-00585-z","article-title":"Autophagy and autophagy-related pathways in cancer","volume":"24","author":"Debnath","year":"2023","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/s41420-023-01496-w","article-title":"Autophagy in BRAF-mutant cutaneous melanoma: Recent advances and therapeutic perspective","volume":"9","author":"Fratta","year":"2023","journal-title":"Cell Death Discov."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"3478","DOI":"10.1158\/1078-0432.CCR-10-2372","article-title":"Measurements of tumor cell autophagy predict invasiveness, resistance to chemotherapy, and survival in melanoma","volume":"17","author":"Ma","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1158\/1078-0432.CCR-11-1282","article-title":"Punctate LC3B expression is a common feature of solid tumors and associated with proliferation, metastasis, and poor outcome","volume":"18","author":"Lazova","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1172\/JCI70454","article-title":"Targeting ER stress-induced autophagy overcomes BRAF inhibitor resistance in melanoma","volume":"124","author":"Ma","year":"2014","journal-title":"J. Clin. Investig."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1080\/15548627.2022.2038899","article-title":"Clinical trial results show promise of targeting autophagy BRAF mutant melanoma","volume":"18","author":"Amaravadi","year":"2022","journal-title":"Autophagy"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1158\/1078-0432.CCR-21-3382","article-title":"BAMM (BRAF Autophagy and MEK Inhibition in Melanoma): A Phase I\/II Trial of Dabrafenib, Trametinib, and Hydroxychloroquine in Advanced BRAFV600-mutant Melanoma","volume":"28","author":"Mehnert","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"ref_26","first-page":"e2677","article-title":"Pogostone Effect on Dacarbazine-Induced Autophagy and Apoptosis in Human Melanoma Cells","volume":"10","author":"Ghanbari","year":"2023","journal-title":"World Cancer Res. J."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"102237","DOI":"10.1016\/j.molmet.2025.102237","article-title":"ACAA1 knockout increases the survival rate of KPC mice by activating autophagy","volume":"100","author":"Lee","year":"2025","journal-title":"Mol. Metab."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"6516","DOI":"10.7150\/thno.114912","article-title":"Loss of SLC25A20 in Pancreatic Adenocarcinoma Reversed the Tumor-Promoting Effects of a High-Fat Diet","volume":"15","author":"Woo","year":"2025","journal-title":"Theranostics"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Kim, S.Y. (2025). Fatty acid addiction in cancer: A high-fat diet directly promotes tumor growth through fatty acid oxidation. Biochim. Biophys. Acta Rev. Cancer, 1880.","DOI":"10.1016\/j.bbcan.2025.189428"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1056\/NEJMoa2109970","article-title":"Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma","volume":"386","author":"Tawbi","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.jid.2022.08.038","article-title":"The Regulators of Peroxisomal Acyl-Carnitine Shuttle CROT and CRAT Promote Metastasis in Melanoma","volume":"143","author":"Feliu","year":"2023","journal-title":"J. Investig. Dermatol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"108421","DOI":"10.1016\/j.celrep.2020.108421","article-title":"Melanoma Persister Cells Are Tolerant to BRAF\/MEK Inhibitors via ACOX1-Mediated Fatty Acid Oxidation","volume":"33","author":"Shen","year":"2020","journal-title":"Cell Rep."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1038\/s41419-022-04593-3","article-title":"The regulation, function, and role of lipophagy, a form of selective autophagy, in metabolic disorders","volume":"13","author":"Zhang","year":"2022","journal-title":"Cell Death Dis."},{"key":"ref_34","unstructured":"Talley, J.T., and Mohiuddin, S.S. (2025). Biochemistry, Fatty Acid Oxidation. StatPearls, StatPearls Publishing."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.semcancer.2022.07.005","article-title":"Cancer depends on fatty acids for ATP production: A possible link between cancer and obesity","volume":"86","author":"Lee","year":"2022","journal-title":"Semin. Cancer Biol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"W556","DOI":"10.1093\/nar\/gkz430","article-title":"GEPIA2: An enhanced web server for large-scale expression profiling and interactive analysis","volume":"47","author":"Tang","year":"2019","journal-title":"Nucleic Acids Res."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"3472","DOI":"10.7150\/thno.53935","article-title":"Overall survival of pancreatic ductal adenocarcinoma is doubled by Aldh7a1 deletion in the KPC mouse","volume":"11","author":"Lee","year":"2021","journal-title":"Theranostics"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"e2511","DOI":"10.1038\/cddis.2016.404","article-title":"Dual targeting of glutaminase 1 and thymidylate synthase elicits death synergistically in NSCLC","volume":"7","author":"Lee","year":"2016","journal-title":"Cell Death Dis."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"8649","DOI":"10.1021\/bi012183n","article-title":"Site-directed mutagenesis and chemical modification of the six native cysteine residues of the rat mitochondrial carnitine carrier: Implications for the role of cysteine-136","volume":"41","author":"Indiveri","year":"2002","journal-title":"Biochemistry"},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Tonazzi, A., Eberini, I., and Indiveri, C. (2013). Molecular mechanism of inhibition of the mitochondrial carnitine\/acylcarnitine transporter by omeprazole revealed by proteoliposome assay, mutagenesis and bioinformatics. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0082286"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1161\/01.RES.86.5.580","article-title":"The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A thiolase","volume":"86","author":"Kantor","year":"2000","journal-title":"Circ. Res."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1002\/pst.426","article-title":"Guidelines for accurate EC50\/IC50 estimation","volume":"10","author":"Sebaugh","year":"2011","journal-title":"Pharm. Stat."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/20\/9873\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T04:12:36Z","timestamp":1760760756000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/20\/9873"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,10]]},"references-count":42,"journal-issue":{"issue":"20","published-online":{"date-parts":[[2025,10]]}},"alternative-id":["ijms26209873"],"URL":"https:\/\/doi.org\/10.3390\/ijms26209873","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,10]]}}}